

Bangkok Dusit Medical Services (BDMS)

Analyst Presentation 4Q19&2019 Results

27 February 2020

Important Notice



- The information contained in this presentation is for information purposes only and does not constitute an offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for share in Bangkok Dusit Medical Services Public Company Limited ("BDMS" and shares in BDMS, "shares") in any jurisdiction nor should it or any part of it from the basis of , or be relied upon in any connection with, any contract or commitment whatsoever.
- This presentation may include information which is forward-looking in nature. Forward-looking information involve known and unknown risks, uncertainties and other factors which may impact on the actual outcomes, including economic conditions in the markets in which BDMS operates and general achievement of BDMS business forecasts, which will cause the actual results, performance or achievements of BDMS to differ, perhaps materially, from the results, performance or achievements expressed or implied in this presentation.
- This presentation has been prepared by the BDMS. The information in this presentation has not been independently verified. No representation, warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information and opinions in this presentation. None of the BDMS or any of its agents or advisors or any of their respective affiliates, advisors or representatives, shall have any liability (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation.
- This presentation is made, furnished and distributed for information purposes only. No part of this presentation shall be relied upon directly or indirectly for any investment decision-making or for any other purposes.
- This presentation and all other information, materials or documents provided in connection therewith, shall not, either in whole or in part, be reproduced, redistributed or made available to any other person, save in strict compliance with all applicable laws.

Contents



BDMS Summary & Updates

COVID-19 Situation

Innovation

Operational Statistics

Financial Performance

BDMS Summary & Updates



BDMS Five-Year Strategy



Key Strategy

- Leverage more on Hub&Spoke
- Focus on Geriatrics care
- Center of Excellence
- Increase occupancy rate
- Expand insurance patient base
- Enlarge non-hospital business



٠

- International medical affiliation
- Smart Virtual Hospital
- Health application



Sustainability


- Quality & safety standard
- Good corporate governance
- Social responsibility



BDMS Five-Year Strategy



Structured Bed Capacity Expansion (CAGR 2010-2024 ~ 8.0%)



* New hospitals

BDMS Center of Excellence (CoE) Network



Adding One More CoE, Bangkok Hospital Sanamchan, to Strengthen Our Network







4Q19 & 2019 Results

	4Q19		2019		
	Chg % to		Chg	% to	
	(yoy)	Revenue	(yoy)	Revenue	
Operating income	+9%		+7%		
	(THB 21,480 mm)		(THB 83,774 mm)		
Patient revenue	+9%		+7%		
	(THB 20,308 mm)		(THB 79,630 mm)		
Breakdown by location					
Bangkok & Vicinity	+7%	58%	+6%	58%	
Outside Bangkok	+13%	42%	+9%	42%	
Breakdown by nationality					
Thai	+12%	70%	+7%	70%	
International	+4%	30%	+7%	30%	
Breakdown by type of patie					
Outpatients	+7%	47%	+6%	46%	
Inpatients	+12%	53%	+7%	54%	





4Q19 & 2019 Profitability Ratio

(THB mm)	4Q19	4Q18	Chg (yoy)	2019	2018	Chg (yoy)
EBITDA *	4,528	3,945	+15%	18,579	17,557	+6%
EBITDA margin *	21.1%	20.0%		22.2%	22.4%	
Core profit	2,373	2,295	3%	10,053	10,136	(1)%
Core profit margin	11.0%	11.6%		12.0%	12.9%	
Non-recurring items	(50)	(945)	n.a.	5,464	(945)	n.a.
Net profit	2,323	1,350	72%	15,517	9,191	+69%
Net profit	10.8%	6.9%		18.5%	11.7%	

^{*} Excluding non-recurring items

2019 Non-recurring items (net of income tax)	THB mm
1. Gain on divestment in RAM	6,094
2. Provisions for employee benefits (400 Days)	(493)
3. One-time expenses in finding the land to locate electricity sub-station	(88)
4. Impairment of trade mark from Save Drug	(50)
4. Gain on sales in other long-term investment	1
Total	5,464

Conditional Voluntary Tender Offer of BH



Transaction Rational

Currently, BDMS held 182.5 mm shares in Bumrungrad Hospital Public Company Limited (BH)
 (approx. 24.99% of total issued and paid-up shares or 21.04% of fully-diluted shares*)

Transaction Rational

- 1. In line with the investment policy of the Company, which focuses on investment in the healthcare business due to Thailand having a competitive advantage in providing healthcare services at a globally accepted standard and competitive pricing in comparison with the quality of services, helping to attract clients from all over the world
- 2. The increase in demand for healthcare services in the region is due to Thailand and neighboring countries' aging society, rising in per capita income, focusing on healthcare services in ensuring longevity and the growing private health insurance
- 3. BH's business demonstrates strong growth potential and has the ability to generate favorable long-term returns, as it is a reputable hospital for treating highly complex diseases, staffed by experienced medical personnel, and is well known to both Thais and foreigners, especially to Middle East and Asia-Pacific countries

¹⁰

Conditional Voluntary Tender Offer of BH



Transaction Rational

- Market condition presents an attractive opportunity to make additional investment in top-tier hospital at reasonable price
 - Conditional Voluntary Tender Offer for all remaining issued and paid-up shares of BH and convertible bonds at the price of THB 125 per share subject to
 - 1) Potential upward revision not exceeding 20% of the Offering Price depending on market conditions and trading price of BH
 - 2) Price adjustment for any special dividend not consistent with BH's past 3 years
 - Offering price at ~34% discount to 52 week high but still at 12% premium to last close at THB 112 per share (26 Feb 2020)

Conditional Voluntary Tender Offer of BH




Transaction Value and Details

Potential transaction value of up to THB 85,613 mm at offering price of THB 125 per share

BH Shares	# Share (mm)	
BDMS Shares	182.5	
Remaining Common Shares	546.3	Takal mumban of shane
Preferred Shares	1.2	Total number of share = 684.9 mm shares
Convertible Bonds	137.4	- 004.9 mm shares

- Conditions Precedent
 - 1. Approval from BDMS shareholders meeting
 - 2. Approval from the Office of Trade Competition Commission (OTCC) (if required)
 - 3. Receipt of financing support from financial institutions
 - 4. No material agreements/amendments of material agreements between BH (or its subsidiaries) and any third party unless in ordinary course of business of BH (or its subsidiaries) and no material adverse effect to BH

COVID-19 Situation



Situation update on COVID-19



COVID-19 confirmed cases (26 Feb 2020; 10 AM BKK time)


Rank	Country/Administrative Region	Confirmed cases	Deaths
1	China	78,064	2,715
2	South Korea	1,146	10
3	Diamond Princess	691	3
4	Italy	322	10
5	Japan	170	1
6	Iran	95	16
7	Singapore	91	-
8	НК	85	2
9	USA	40	-
10	Thai	40 (recovered 24)	-
	Global	80,994	2,760

Source: Department of Disease Control

Situation update on COVID-19



BDMS Screening of Patient with Possible COVID-19



COVID-19 impact



COVID-19 impact

- Short-term negative impact
- Fly-in patients avoid travelling during epidemic widespread



Innovation



Innovation: Healthy Bot



Preventing the Spread of Outbreak






- As part of an effort to prevent outbreak from spreading, BDMS deployed Healthy Bot, equipped with a camera and microphone, to connect patients under investigation in isolation unit to reduce human contact and to avoid cross infection
- The smart robot, available 24 hours, also helps ease the workload of clinical staffs

Innovation: Healthy Bot



Key Services



- Equipped with camera for Face to Face consultation with our doctors
- VDO call with family members

Innovation: Smart Mobile Medication Cart



BDMS-SCG Collaboration Project



Key Features

- Modern Design
 - Enhance premium brand position
- Patient Safety
 - Barcode reader for patient identification matching with correct medication drawer
 - Medication drawers temperature controlled to ensure medication quality
- Hygiene
 - Anti-microbial material properties
 - Ease of cleaning
- Easy to Operate and Maintain
 - Workspace and pockets for equipment and supplies
 - Long battery life


Operational Statistics





Operating Income Trend

(THB mm)



Commentary

- 2019 Operating income increased by 7% yoy mainly from
 - Patient revenue increased 7% yoy, attributed to
 - Increase insurance patient base of 12% yoy (Thai insurance grew 13% while international insurance grew 11%)
 - Higher revenue from hospitals outside Bangkok of 9% yoy
 - Increase in both Thai and International patient revenue of 7% yoy

Thai and International Patients





Revenue Contribution by Nationality

Top 5 Nationality contribution in 2019

% to patient revenue

% to patient revenue






Commentary


- In 2019, strong growth from both Thai patients and international patients of 7% yoy
 - Key growth for International patient revenues are UAE (+56%), Oman (+56%) and Cambodia (+16% yoy)



Revenue Breakdown by Patient Types




Patient Revenue by Payor: Increasing Insurance Portion




Increasing Patient Volume



Number of OPD Visits per Day




Average Daily Census (ADC)



Utilization of Beds



Occupancy Rate Based on Available Beds




Average Length of Stay (days)



Remarks:- Including social security patients

Financial Highlights




Diversified Sources of Revenues and Profitability



COE Operating Income Contribution in 2019

COE Total EBITDA Contribution in 2019



Commentary

- In 2019, 10 Center of Excellence (COE) contributed 50% of total revenues and 55% of total EBITDA
- Key hospitals that drive revenue growth were PLK (+31%), STH (+23%), SCH (+22%), PLR (+21%), BCM (+20%) and RPH (+19% yoy)


^{*} SVNH included SVH and SNH performance

Profitability Trend



EBITDA & EBITDA Margin *


(THB mm)



 EBITDA margin decreased slightly from 22.4% in 2018 to 22.2% in 2019

EBIT & EBIT Margin *

(THB mm)




In 2019, EBIT margin decreased due mainly to divestment of all investment in RAM during 1Q19

^{*} Excluding non-recurring items



Core Profit & Core Profit Margin

(THB mm)




Commentary

- In 2019, core profit were THB 10,053 million with core profit margin of 12.0%
- If included non-recurring items totaling of THB 5,464 million, net profit was THB 15,517 million with net profit margin of 18.5%

Capital Management

Bangkok Dusit Medical Services

Capital Structure as of December 2019



Gearing Ratios: Well Within Covenants

2015

2016

Net Debt/EBITDA

Net debt/EBITDA convenant < 3.25x 2.2 2.0 Net debt/equity convenant < 1.75x 0.4 0.5 0.5 0.5 0.2


2017

2018

→ Net Debt/Equity

2019

Dividend Payment & Payout Ratio



* Board of Directors had resolution on 26 February 2020 to propose for dividend payment of Baht 0.55 per share

Interest Coverage





For More Information:- www.bangkokhospital.com

Group 1 (Bangkok&West&Cambodia)	Ownership No	o. of Beds	Group 4 (North&Northeast)	Ownership	No. of Beds
1. Bangkok Hospital	100%		28. Bangkok Udon (BUD)	100%	120
2. Bangkok Heart Hospital	100%	97	29. Bangkok Phitsanulok (BPL)	100%	195
3. Wattanosoth Hospital - (BHQ)	100% 🧼	48	30. Bangkok Khon Kaen (BKN)	100%	140
4. Chiva Transitional Care	100%	52	31. Bangkok Chiangrai (BCR)	100%	80
5. Bangkok International	100%	172	Group 5		
6. Bangkok Huahin (BHN)	100%	61	32. Phyathai 1 (PT1)	98.6%	224
7. Bangkok Sanamchan (BSN)	100%	210	33. Phyathai 2 (PT2)	97.8%	
8. Thepakorn (TPK)	50.0%	100	34. Phyathai 3 (PT3)	97.6%	267
9. Bangkok Phetchaburi (BPR)	100%	255	35. Phyathai Sriracha (PTS)	74.2%	350
10. Bangkok Muangraj (BMR)	100%	1/17	36. Phyathai Nawamin (PTN)	99.8%	140
11. Royal Phnom Penh (RPH)	100%	100	37. Paolo Paholyothin (PLP)	100%	267
12. Royal Angkor International (RAH)	80.0%	20	38. Paolo Samutprakarn(PLS)	93.7%	200
Group 2			39. Paolo Chokchai 4 (PLC)	85.7%	169
13. Samitivej Sukhumvit (SVH)	95.8%	211	40. Paolo Rangsit (PLR)	100%	150
14. Samitivej Srinakarin (SNH)	95.8%	400	41. Paolo Kaset (PLK)	100%	162
15. Samitivej Sriracha (SSH)	70.1 % 📀 :	101	42. Paolo Phrapradaeng (PLD)	84.0%	60
16. Samitivej Thonburi (STH)	63.5%	150		04.070	00
17. Samitivej Chonburi (SCH)	100%	<i>//</i> U -	Group 6 (South)	00 70/	266
18. Samitivej Chinatown (SCT)	100%	39	43. Bangkok Phuket (BPK)	99.7% ②	
19. BNH Hospital (BNH)	91.5%	144	44. Bangkok Siriroj (BSI)	20070	131
Group 3 (East)			45. Dibuk (DBK)	99.7%	100
20. Bangkok Pattaya (BPH)	97.3%	400	46. Bangkok Hat Yai (BHH)	98.8%	200
21. Bangkok Rayong (BRH)	100%	220	47. Bangkok Samui (BSH)	100%	52
22. Bangkok Chanthaburi (BCH)	99.7%	1/0	48. Bangkok Surat (BSR)	100%	150
23. Bangkok Trat (BTH)	99.8%	114 -	Group 7: Non-Hospital		
24. Sri Rayong (SRH)	100%	190	National Healthcare System	100%	
Group 4 (North&Northeast)			2. Bio Molecular Laboratories	95.0%	
25. Bangkok Chiangmai (BCM)	100%	1/5	3. The Medicpharma	87.1%	
26. Bangkok Ratchasima (BKH)		180	4. A.N.B Laboratories	100%	
27. Bangkok Pakchong (BHP)	91.4%	31	5. Save Drug Center (SDC)	100%	32
Pomark: Number of hads is structured hads			6. General Hospital Products	47.0%	32

Remark:- Number of beds is structured beds







น้ำยาทำความสะอาคมือ

หาซื้อได้ที่ Save Drug สาขา N Space

Double Action











- ออกฤทธิ์เร็ว 15 วินาที
- ปกป้องได้นาน 6 ชั่วโมง
- แห้งเร็ว ไม่เหนียวมือ
- มี Moisturizer
 ไม่ทำให้มือแห้งแตก

- ฆ่าเชื้อไวรัส
- ฆ่าเชื้อแบคทีเรีย
- ฆ่าเชื้อรา



HANDI-C ประกอบด้วยตัวยาสำคัญ

- Chlorhexidine Gluconate 0.5%
- Alcohol 70%

เป็นสินค้าที่โรงพยาบาลใช้ในห้องผ่าตัด